StocksMedium•4 November 2026•
1 min read
Relay Therapeutics Reports Zero Revenue for Q3 2026
Key Facts
1Relay Therapeutics reported third-quarter revenue of $0 for 2026.
2The company missed the FactSet consensus revenue estimate of $1.6 million.
Relay Therapeutics reported third-quarter revenue of $0 for 2026. According to Benzinga, the company missed the FactSet consensus revenue estimate of $1.6 million.
RLAY closed at $17.44 on November 3, 2026, with a session high of $18.01 and a low of $17.28. The zero-revenue result reflects the company's current clinical stage, where revenue generation remains inconsistent.